Hui Shen1, Liping Xia, Jing Lu, Weiguo Xiao. 1. Department of Rheumatology and Immunology, 1st Affiliated Hospital of China Medical University, Shenyang, China. shenhuicam@sohu.com
Abstract
BACKGROUND: To detect frequency changes in interleukin 17 (IL-17)(+) CD4(+) T cells and the amounts of IL-17 in supernatants between baseline and 30 weeks after Infliximab combined with methotrexate (MTX) or MTX-alone therapy. METHODS: Flow cytometry was used to analyze the frequency of IL-17(+) CD4(+) T cells in rheumatoid arthritis (RA) patients and control subjects at baseline and 30 weeks after therapy. Secretion of IL-17 by peripheral blood mononuclear cells was measured by enzyme-linked immunosorbent assay. RESULTS: The percentages of IL-17(+) CD4(+)T cells were increased in the peripheral blood mononuclear cells of patients with RA compared with healthy subjects. The percentages of IL-17(+) CD4(+)T cells were correlated with the number of swelling joints and C-reactive protein of RA patients. Likewise, concentrations of IL-17 in supernatants from patients with RA were significantly higher compared with those from control subjects. After infliximab combined with MTX or MTX-alone therapy, the number of swelling joints, erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, and Disease Activity Score 28 decreased significantly compared with baseline. Only in the infliximab + MTX group that the frequency of T(H)17 cells and concentration of IL-17 decreased. CONCLUSIONS: These data support the hypothesis that infliximab therapy can have an effect on T(H)17 cells and decrease disease activity.
BACKGROUND: To detect frequency changes in interleukin 17 (IL-17)(+) CD4(+) T cells and the amounts of IL-17 in supernatants between baseline and 30 weeks after Infliximab combined with methotrexate (MTX) or MTX-alone therapy. METHODS: Flow cytometry was used to analyze the frequency of IL-17(+) CD4(+) T cells in rheumatoid arthritis (RA) patients and control subjects at baseline and 30 weeks after therapy. Secretion of IL-17 by peripheral blood mononuclear cells was measured by enzyme-linked immunosorbent assay. RESULTS: The percentages of IL-17(+) CD4(+)T cells were increased in the peripheral blood mononuclear cells of patients with RA compared with healthy subjects. The percentages of IL-17(+) CD4(+)T cells were correlated with the number of swelling joints and C-reactive protein of RApatients. Likewise, concentrations of IL-17 in supernatants from patients with RA were significantly higher compared with those from control subjects. After infliximab combined with MTX or MTX-alone therapy, the number of swelling joints, erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, and Disease Activity Score 28 decreased significantly compared with baseline. Only in the infliximab + MTX group that the frequency of T(H)17 cells and concentration of IL-17 decreased. CONCLUSIONS: These data support the hypothesis that infliximab therapy can have an effect on T(H)17 cells and decrease disease activity.
Authors: Ariana Barberá; Noraylis Lorenzo; Peter van Kooten; Joel van Roon; Wilco de Jager; Dinorah Prada; Jorge Gómez; Gabriel Padrón; Willem van Eden; Femke Broere; María Del Carmen Domínguez Journal: Cell Stress Chaperones Date: 2016-05-30 Impact factor: 3.667
Authors: Veera Hölttä; Taina Sipponen; Mia Westerholm-Ormio; Harri M Salo; Kaija-Leena Kolho; Martti Färkkilä; Erkki Savilahti; Outi Vaarala; Paula Klemetti Journal: ISRN Gastroenterol Date: 2012-06-14
Authors: Agata Kosmaczewska; Jerzy Swierkot; Lidia Ciszak; Aleksandra Szteblich; Agnieszka Chrobak; Lidia Karabon; Anna Partyka; Jacek Szechinski; Piotr Wiland; Irena Frydecka Journal: Rheumatol Int Date: 2013-11-13 Impact factor: 2.631